Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06453577

Pharmacokinetics of Bisoprolol and SGLT2i in Acutely Decompensated Heart Failure

Pharmacokinetics and Pharmacodynamics of Bisoprolol and SGLT2-Inhibitors (Dapagliflozin, Empagliflozin) in Acutely Decompensated Heart Failure BISO-ADHF (BI=BIsoprolol, SO=Sodium-glucose Co-transporter-2 Inhibitors in Acute Decompensated Heart Failure)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
12 (estimated)
Sponsor
Universität des Saarlandes · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

The pharmacokinetics (PK) and pharmacodynamics (PD) of bisoprolol and sodium-glucose co-transporter-2 inhibitors (SGLT2i, dapagliflozin and empagliflozin) in patients with acutely decompensated heart failure (ADHF), compared to the recompensated state, is unknown. If not in cardiogenic shock (no need of vasopressor (catechoalmines) therapy or other inotropic support), established oral betablocker therapy should de continued. Whether this holds true for SGLT2i in ADHF is less clear but current evidence suggest safety and potentially beneficial effects in doing so. To the best of our knowledge, no data regarding PK/PD are available for the most widely used beta blocker bisoprolol and the newly approved/in Germany available SGLT2i Dapagliflozin and Empagliflozin. This study shall provide first evidence on the PK/PD-profile of p.o. bisoprolol and SGLT2i (dapaglifozin or empagliflozin) regarding acute (hemodynamic) effects and safety as well as to provide data on dose recommendations eventually in patients with ADHF.

Conditions

Interventions

TypeNameDescription
DRUGRecompensation (guideline directed medical therapy)Recompensation mainly achieved by intravenous diuretics and/or vasodilators but no requirement for positive inotropic drugs such as catecholamines or levosimendan.

Timeline

Start date
2023-05-01
Primary completion
2025-12-31
Completion
2025-12-31
First posted
2024-06-11
Last updated
2025-06-10

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT06453577. Inclusion in this directory is not an endorsement.